The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA)…
Public Health Initiative, A Registered Non-profit organization – All Right Reserved. 2011-2024. Contact us.